Chemoprophylaxis Vaccination: Phase I Study to Explore Stage-specific Immunity to Plasmodium falciparum in US Adults.
Plasmodium falciparum
chemoprophylaxis vaccination with sporozoites
chloroquine
malaria
primaquine
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
12 09 2020
12 09 2020
Historique:
received:
25
06
2019
accepted:
11
10
2019
pubmed:
18
10
2019
medline:
28
4
2021
entrez:
18
10
2019
Statut:
ppublish
Résumé
Chemoprophylaxis vaccination with sporozoites (CVac) with chloroquine induces protection against a homologous Plasmodium falciparum sporozoite (PfSPZ) challenge, but whether blood-stage parasite exposure is required for protection remains unclear. Chloroquine suppresses and clears blood-stage parasitemia, while other antimalarial drugs, such as primaquine, act against liver-stage parasites. Here, we evaluated CVac regimens using primaquine and/or chloroquine as the partner drug to discern whether blood-stage parasite exposure impacts protection against homologous controlled human malaria infection. In a Phase I, randomized, partial double-blind, placebo-controlled study of 36 malaria-naive adults, all CVac subjects received chloroquine prophylaxis and bites from 12-15 P. falciparum-infected mosquitoes (CVac-chloroquine arm) at 3 monthly iterations, and some received postexposure primaquine (CVac-primaquine/chloroquine arm). Drug control subjects received primaquine, chloroquine, and uninfected mosquito bites. After a chloroquine washout, subjects, including treatment-naive infectivity controls, underwent homologous, PfSPZ controlled human malaria infection and were monitored for parasitemia for 21 days. No serious adverse events occurred. During CVac, all but 1 subject in the study remained blood-smear negative, while only 1 subject (primaquine/chloroquine arm) remained polymerase chain reaction-negative. Upon challenge, compared to infectivity controls, 3/3 chloroquine arm subjects displayed delayed patent parasitemia (P = .01) but not sterile protection, while 3/11 primaquine/chloroquine subjects remained blood-smear negative. CVac-primaquine/chloroquine is safe and induces sterile immunity to P. falciparum in some recipients, but a single 45 mg dose of primaquine postexposure does not completely prevent blood-stage parasitemia. Unlike previous studies, CVac-chloroquine did not produce sterile immunity. NCT01500980.
Sections du résumé
BACKGROUND
Chemoprophylaxis vaccination with sporozoites (CVac) with chloroquine induces protection against a homologous Plasmodium falciparum sporozoite (PfSPZ) challenge, but whether blood-stage parasite exposure is required for protection remains unclear. Chloroquine suppresses and clears blood-stage parasitemia, while other antimalarial drugs, such as primaquine, act against liver-stage parasites. Here, we evaluated CVac regimens using primaquine and/or chloroquine as the partner drug to discern whether blood-stage parasite exposure impacts protection against homologous controlled human malaria infection.
METHODS
In a Phase I, randomized, partial double-blind, placebo-controlled study of 36 malaria-naive adults, all CVac subjects received chloroquine prophylaxis and bites from 12-15 P. falciparum-infected mosquitoes (CVac-chloroquine arm) at 3 monthly iterations, and some received postexposure primaquine (CVac-primaquine/chloroquine arm). Drug control subjects received primaquine, chloroquine, and uninfected mosquito bites. After a chloroquine washout, subjects, including treatment-naive infectivity controls, underwent homologous, PfSPZ controlled human malaria infection and were monitored for parasitemia for 21 days.
RESULTS
No serious adverse events occurred. During CVac, all but 1 subject in the study remained blood-smear negative, while only 1 subject (primaquine/chloroquine arm) remained polymerase chain reaction-negative. Upon challenge, compared to infectivity controls, 3/3 chloroquine arm subjects displayed delayed patent parasitemia (P = .01) but not sterile protection, while 3/11 primaquine/chloroquine subjects remained blood-smear negative.
CONCLUSIONS
CVac-primaquine/chloroquine is safe and induces sterile immunity to P. falciparum in some recipients, but a single 45 mg dose of primaquine postexposure does not completely prevent blood-stage parasitemia. Unlike previous studies, CVac-chloroquine did not produce sterile immunity.
CLINICAL TRIALS REGISTRATION
NCT01500980.
Identifiants
pubmed: 31621832
pii: 5588862
doi: 10.1093/cid/ciz1010
pmc: PMC7486848
doi:
Substances chimiques
Antimalarials
0
Banques de données
ClinicalTrials.gov
['NCT01500980']
Types de publication
Clinical Trial, Phase I
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1481-1490Subventions
Organisme : Intramural NIH HHS
ID : ZIA AI001170
Pays : United States
Informations de copyright
Published by Oxford University Press for the Infectious Diseases Society of America 2019.
Références
J Chromatogr. 1983 Nov 11;278(1):81-9
pubmed: 6662888
Am J Trop Med Hyg. 2018 Jun;98(6):1705-1708
pubmed: 29714158
Science. 2013 Sep 20;341(6152):1359-65
pubmed: 23929949
N Engl J Med. 2009 Jul 30;361(5):468-77
pubmed: 19641203
Nature. 2017 Feb 23;542(7642):445-449
pubmed: 28199305
Am J Trop Med Hyg. 1986 Jan;35(1):66-8
pubmed: 3511753
Lancet. 2011 May 21;377(9779):1770-6
pubmed: 21514658
Am J Trop Med Hyg. 2012 Mar;86(3):383-94
pubmed: 22403305
Trans R Soc Trop Med Hyg. 1974;68(3):258-9
pubmed: 4608063
Nat Med. 2016 Jun;22(6):614-23
pubmed: 27158907
PLoS Pathog. 2011 Dec;7(12):e1002389
pubmed: 22144890
Am J Med Sci. 1973 Sep;266(3):169-77
pubmed: 4583408
J Infect Dis. 2014 Nov 15;210(10):1605-15
pubmed: 24872326
BMC Med. 2017 Sep 13;15(1):168
pubmed: 28903777
J Infect Dis. 2002 Apr 15;185(8):1155-64
pubmed: 11930326
J Lab Clin Med. 1955 Sep;46(3):391-7
pubmed: 13252317
JCI Insight. 2017 Jan 12;2(1):e89154
pubmed: 28097230
PLoS One. 2014 Feb 07;9(2):e88117
pubmed: 24516592
Vaccine. 2009 Jan 1;27(1):2-9
pubmed: 18973784
J Lab Clin Med. 1955 Aug;46(2):301-6
pubmed: 13242948
PLoS One. 2014 Nov 14;9(11):e112910
pubmed: 25396417
Proc Natl Acad Sci U S A. 2013 May 7;110(19):7862-7
pubmed: 23599283
J Infect Dis. 2007 Jul 1;196(1):145-54
pubmed: 17538895
PLoS One. 2014 Nov 18;9(11):e109654
pubmed: 25405724
Malar J. 2014 Mar 12;13:92
pubmed: 24620841
Malar J. 2014 Apr 05;13:136
pubmed: 24708526